Keliximab
Based on 1 Customer Validation
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research.
For research use only. We do not sell to patients.
- Purity: 98.23%
- CAS No.: 174722-30-6
- Molecular Weight:144.12 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 lambda
Human
CD4
Keliximab shows a Kd value of 1.0 nM for binding with soluble CD4 (sCD4)[2]. Keliximab (0.01-10 μg/mL; 30 min) dose-dependently binds to the CD4+ thymoma cell line SupT1 with an ED50 of 0.2 μg/mL[1]. Keliximab (0-1000 ng/mL) blocks T cell proliferation and IL-2 production with IC50s of 10-30 ng/mL in primary human plasmablastic lymphomas (PBLs)[1]. Keliximab (1-1000 ng/mL; 5 min) dose-dependently mediates cell-cell adhesion with an ED50 value of 20 ng/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Transgenic mice bearing human CD4 molecules on their T cells[1]
-
Dosage:5-125 mg/kg
-
Administration:Intravenous injection, 5-125 mg/kg, once
-
Result:Dose-dependently down-modulated CD4 and rapidly declined the number of circulating CD4+ T cells compared with clenoliximab.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1.5X106 THP-1 cells labeling Keliximab (HY-P99680, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda1 (HY-P99992, blue) was used as the isotype control.
Chemical Information
-
CAS No. 174722-30-6
-
Appearance Liquid
-
Molecular Weight 144.12 kDa
-
Color Colorless to light yellow
-
SMILES
[Keliximab]
-
Synonyms
SB-210396; IDEC CE9.1
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41. [Content Brief]
[2]. Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)